Upcoming data from a mid-stage study of Amgen’s experimental weight-loss drug MariTide will shed light on how well it could measure up against popular drugs sold by Eli Lilly and Novo Nordisk. Amgen’s encouraging comments about the phase 2 trial helped drive an 8% rise in the company’s stock over the past year.